- Publications
- Influence
Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications.
- Toshimichi Nakamura, Takeo Nakanishi, Tsunemitsu Haruta, Yoshiyuki Shirasaka, John P Keogh, Ikumi Tamai
- Molecular pharmaceutics
- 2010
Ipratropium bromide, an anticholinergic drug used for the treatment of asthma and chronic obstructive pulmonary disease, has low oral bioavailability, but systemic exposure, superior to oral… (More)
- Toshimichi Nakamura, Kenji Yoshida, Hikaru Yabuuchi, Tomoji Maeda, Ikumi Tamai
- Biological & pharmaceutical bulletin
- 2008
It has been reported that organic cation/carnitine transporter 1 (OCTN1) is associated with rheumatoid arthritis and Crohn's disease. Additionally, we reported that OCTN1 is expressed in… (More)
- Toshimichi Nakamura, Shigeki Sugiura, +5 authors Ikumi Tamai
- Pharmaceutical Research
- 2007
PurposeRecently, it was reported that OCTN1 transporter (SLC22A4) is associated with rheumatoid arthritis (RA) and Crohn’s disease. Additionally, we reported that OCTN1 is expressed in hematopoietic… (More)
- Toshimichi Nakamura, Ryohei Fujiwara, +5 authors Ikumi Tamai
- Biological & pharmaceutical bulletin
- 2010
Phosphatidylcholine (PC) production is accelerated by glucocorticoid, such as dexamethasone (DEX), which enhances fetal lung maturation, promotes differentiation of alveolar type II (ATII) cells, and… (More)
- Keisuke Mitsuoka, Yoshiyuki Shirasaka, +4 authors Ikumi Tamai
- Biopharmaceutics & drug disposition
- 2009
L-Citrulline has diagnostic potential for renal function, because its plasma concentration increases with the progression of renal failure. Although L-citrulline extracted by glomerular filtration in… (More)
- Toshimichi Nakamura, Kenji Yoshida, +5 authors Ikumi Tamai
- 2006
- Toshimichi Nakamura, Kota Toshimoto, Wooin Lee, Chiyo K. Imamura, Yusuke Tanigawara, Yuichi Sugiyama
- CPT: pharmacometrics & systems pharmacology
- 2018
The Tamoxifen Response by CYP2D6 Genotype-based Treatment-1 (TARGET-1) study (n = 180) was conducted from 2012-2017 in Japan to determine the efficacy of tamoxifen dosing guided by cytochrome P450… (More)